Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer therapeutics - Ryvu Therapeutics

Next Previous
Drug Profile

Research programme: anti-cancer therapeutics - Ryvu Therapeutics

Alternative Names: A2A/B antagonists - Ryvu Therapeutics; Adenosine pathway modulators - Ryvu Therapeutics; Dual A2A/A2B adenosine receptor antagonists - Ryvu Therapeutics; Dual A2A/A2B antagonists - Ryvu Therapeutics; RVU 330; Serine hydroxymethyltransferase 2 inhibitors - Ryvu Therapeutics; SHMT2 inhibitors - Ryvu Therapeutics

Latest Information Update: 27 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selvita
  • Developer Ryvu Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists; Immunomodulators; SHMT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 27 Sep 2023 Discontinued - Preclinical for Cancer in Poland (unspecified route)
  • 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in Poland
  • 04 Oct 2019 Selvita is now called Ryvu Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top